AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Articles
August 28, 2015

Dual antiplatelet therapy in stroke and ICAS
Subgroup analysis of CHANCE

Liping Liu, MD, Ka Sing Lawrence Wong, MD, Xinyi Leng, PhD, Yuehua Pu, MD, Yilong Wang, MD, Jing Jing, MD, Xinying Zou, MD, … Show All … , Yuesong Pan, MD, Anxin Wang, MS, Xia Meng, MD, Chunxue Wang, MD, Xingquan Zhao, MD, Yannie Soo, MD, S. Claiborne Johnston, MD, and Yongjun Wang, MD For the CHANCE InvestigatorsAuthors Info & Affiliations
September 29, 2015 issue
85 (13) 1154-1162
https://doi.org/10.1212/WNL.0000000000001972
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Objective:

We aimed to investigate whether the efficacy and safety of clopidogrel plus aspirin vs aspirin alone were consistent between patients with and without intracranial arterial stenosis (ICAS), in the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial.

Methods:

We assessed the interaction of the treatment effects of the 2 antiplatelet therapies among patients with and without ICAS, identified by magnetic resonance angiography (MRA) in CHANCE (ClinicalTrials.gov identifier NCT00979589).

Results:

Overall, 1,089 patients with MRA images available in CHANCE were included in this subanalysis, 608 patients (55.8%) with ICAS and 481 (44.2%) without. Patients with ICAS had higher rates of recurrent stroke (12.5% vs 5.4%; p < 0.0001) at 90 days than those without. But there was no statistically significant treatment by presence of ICAS interaction on either the primary outcome of any stroke (hazard ratio for clopidogrel plus aspirin vs aspirin alone: 0.79 [0.47–1.32] vs 1.12 [0.56–2.25]; interaction p = 0.522) or the safety outcome of any bleeding event (interaction p = 0.277).

Conclusions:

The results indicated higher rate of recurrent stroke in minor stroke or high-risk TIA patients with ICAS than in those without. However, there was no significant difference in the response to the 2 antiplatelet therapies between patients with and without ICAS in the CHANCE trial.

Classification of evidence:

This study provides Class II evidence that for patients with acute minor stroke or TIA with and without ICAS identified by MRA, clopidogrel plus aspirin is not significantly different than aspirin alone in preventing recurrent stroke.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (coinvestigators.docx)
File (figure_e-1.pdf)
File (table_e-1.pdf)

REFERENCES

1.
Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial. Circulation 2005;111:2233–2240.
Crossref
PubMed
Google Scholar
2.
Wong KS, Chen C, Fu J, et al. Clopidogrel Plus Aspirin Versus Aspirin Alone for Reducing Embolisation in Patients with Acute Symptomatic Cerebral or Carotid Artery Stenosis (CLAIR Study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489–497.
Crossref
PubMed
Google Scholar
3.
Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19.
Crossref
PubMed
Google Scholar
4.
Feske SK. A little good. Circulation 2013;128:1598–1599.
Crossref
PubMed
Google Scholar
5.
Hankey GJ. Dual antiplatelet therapy in acute transient ischemic attack and minor stroke. N Engl J Med 2013;369:82–83.
Crossref
PubMed
Google Scholar
6.
Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010;160:380–386.
Crossref
PubMed
Google Scholar
7.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med 1993;329:673–682.
Crossref
PubMed
Google Scholar
8.
Samuels OB, Joseph GJ, Lynn MJ, Smith HA, Chimowitz MZ. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol 2000;21:643–646.
PubMed
Google Scholar
9.
Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke 2014;45:663–669.
Crossref
PubMed
Google Scholar
10.
Wong KS, Li H, Chan YL, et al. Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke 2000;31:2641–2647.
Crossref
PubMed
Google Scholar
11.
Qureshi AI, Feldmann E, Gomez CR, et al. Intracranial atherosclerotic disease: an update. Ann Neurol 2009;66:730–738.
Crossref
PubMed
Google Scholar
12.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.
Crossref
PubMed
Google Scholar
13.
Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817–825.
Crossref
PubMed
Google Scholar
14.
Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013;128:1656–1666.
Crossref
PubMed
Google Scholar
15.
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–969.
Crossref
PubMed
Google Scholar
16.
Johnston SC, Easton JD, Farrant M, et al. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: rationale and design. Int J Stroke 2013;8:479–483.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 85 • Number 13 • September 29, 2015
Pages: 1154-1162
PubMed: 26330567

Copyright

© 2015 American Academy of Neurology.

Publication History

Received: February 3, 2015
Accepted: June 3, 2015
Published online: August 28, 2015
Published in print: September 29, 2015

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Study Funding

Supported by grants 2008ZX09312-008, 2011BAI08B02, 2012ZX09303, and 200902004 from the Ministry of Science and Technology, China; and the Chinese University of Hong Kong (Focused Investment Scheme B) and the Institute of Innovative Medicine, Chinese University of Hong Kong, China.

Authors

Affiliations & Disclosures

Liping Liu, MD*
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
editor of Jouenals Stroke, Neuroepidemiology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ka Sing Lawrence Wong, MD*
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Pfizer, Sanofi
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Pfizer, Sanofi
Editorial Boards:
1.
Associate Editor, STROKE, Neurology Asia Ed Board: JNNP, Eur J Neurology, Journal Neuroimaging
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Xinyi Leng, PhD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yuehua Pu, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yilong Wang, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Dr. Yilong Wang received research support from the Ministry of Science and Technology of the People's Republic of China (No. 2011BAI08B02, 2011-2015). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jing Jing, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Xinying Zou, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yuesong Pan, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anxin Wang, MS
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Xia Meng, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Chunxue Wang, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Xingquan Zhao, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yannie Soo, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
S. Claiborne Johnston, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
INTERACT trial DSMB member (funded by NHMRC of Australia)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal Watch Neurology, Co-Editor-in-Chief Annals of Neurology, Vice Editor
Patents:
1.
Co-holder of patent on the RNA panel to identify TIA and risk stratify.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
AstraZeneca; Sanofi (for drug and placebo donation to an NIH- sponsored trial).
Research Support, Government Entities:
1.
(1) NCRR/NCATS, CTSA, PI 2008-2014; (2) NINDS/U01, POINT Trial, PI, 2009-current
Research Support, Academic Entities:
1.
Kaiser-Permanente Adjunct Investigator
Research Support, Foundations and Societies:
1.
Grove Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Yongjun Wang, MD
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
For the CHANCE Investigators
From the Department of Neurology (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Center for Neurological Diseases (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing; Center of Stroke (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang), Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease (L.L., Yuehua Pu, Yilong Wang, J.J., Xinying Zou, Yuesong Pan, A.W., X.M., C.W., Xingquan Zhao, Yongjun Wang); Department of Medicine and Therapeutics (K.S.L.W., X.L., Y.S.), the Chinese University of Hong Kong, China; and Dell Medical School (S.C.J.), The University of Texas at Austin.
View all articles by this author

Notes

Correspondence to Dr. Yongjun Wang: [email protected]
*
These authors contributed equally to this work.
CHANCE coinvestigators are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Liping Liu and Dr. Ka Sing Lawrence Wong contributed to study design, literature search, data analysis, data interpretation, and manuscript preparation. Dr. Xinyi Leng contributed to literature search, data analysis and interpretation, figures, and manuscript preparation. Dr. Yuehua Pu contributed to data collection and interpretation and manuscript preparation. Dr. Yilong Wang contributed to study design and data interpretation, and provided critical and essential comments on the manuscript. Dr. Jing Jing and Dr. Xinying Zou contributed to data collection and image analysis and interpretation. Dr. Yuesong Pan and Mr. Anxin Wang contributed to statistical analysis, data interpretation, and figures. Dr. Xia Meng contributed to data collection and image interpretation. Dr. Chunxue Wang, Dr. Xingquan Zhao, and Dr. Yannie Soo contributed to study design and provided critical and essential comments on the manuscript. Dr. S. Claiborne Johnston and Dr. Yongjun Wang were the principal investigators of the CHANCE study, and contributed to study design, data analysis and interpretation, and provided critical comments on the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Jiejie Li,
    • Yuesong Pan,
    • Mengxing Wang,
    • Xia Meng,
    • Jinxi Lin,
    • Zixiao Li,
    • Hao Li,
    • Yilong Wang,
    • Xingquan Zhao,
    • Liping Liu,
    • Yongjun Wang,
    High-Sensitivity C-reactive Protein and Intracranial Arterial Stenosis Predicted Recurrent Stroke and Dependence or Death in Minor Stroke or Transient Ischemic Attack, Journal of Atherosclerosis and Thrombosis, 31, 3, (249-258), (2024).https://doi.org/10.5551/jat.64229
    Crossref
    • Marcin Piechocki,
    • Tadeusz Przewłocki,
    • Piotr Pieniążek,
    • Mariusz Trystuła,
    • Jakub Podolec,
    • Anna Kabłak-Ziembicka,
    A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory, Journal of Clinical Medicine, 13, 5, (1508), (2024).https://doi.org/10.3390/jcm13051508
    Crossref
    • Shuang Qi,
    • Liang Liu,
    • Fei-Xue Yue,
    • Jing Qiu,
    • Wei Li,
    • Chao Li,
    • Thanh N. Nguyen,
    • Ming Wei,
    • Hui-Sheng Chen,
    • Shou-Chun Wang,
    Balloon angiopLasty for intracranial Atherosclerotic minor Stroke/TIA (BLAST): study protocol for a multicenter prospective cohort study, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1385546
    Crossref
    • Liying Sun,
    • Xuhui Ye,
    • Junping Yu,
    • Linlin Wang,
    • Yan Wu,
    • Jing Cui,
    • Lihua Dai,
    Peripheral Lymphocyte-to-Monocyte Ratio as a Predictive Factor for Early Neurological Deterioration in Patients with Acute Ischemic Stroke, International Journal of General Medicine, Volume 17, (4397-4405), (2024).https://doi.org/10.2147/IJGM.S483064
    Crossref
    • Joanna M Wardlaw,
    • Hugues Chabriat,
    • Frank-Erik de Leeuw,
    • Stéphanie Debette,
    • Martin Dichgans,
    • Fergus Doubal,
    • Hanna Jokinen,
    • Aristeidis H Katsanos,
    • Raffaele Ornello,
    • Leonardo Pantoni,
    • Marco Pasi,
    • Aleksandra M Pavlovic,
    • Salvatore Rudilosso,
    • Reinhold Schmidt,
    • Julie Staals,
    • Martin Taylor-Rowan,
    • Salman Hussain,
    • Arne G Lindgren,
    European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke, European Stroke Journal, 9, 1, (5-68), (2024).https://doi.org/10.1177/23969873231219416
    Crossref
    • Abeer Dagra,
    • Brandon Lucke‐Wold,
    • Kyle McGrath,
    • Ilyas Mehkri,
    • Yusuf Mehkri,
    • Caroline Grace Davidson,
    • Noah Gilberstadt,
    • Bobby W. Douglas,
    • Brian Hoh,
    Central Retinal Artery Occlusion: A Review of Pathophysiological Features and Management, Stroke: Vascular and Interventional Neurology, 4, 1, (2024).https://doi.org/10.1161/SVIN.123.000977
    Crossref
    • Shadi Yaghi,
    • Catherine Albin,
    • Seemant Chaturvedi,
    • Sean I. Savitz,
    Roundtable of Academia and Industry for Stroke Prevention: Prevention and Treatment of Large-Vessel Disease, Stroke, 55, 1, (226-235), (2024).https://doi.org/10.1161/STROKEAHA.123.043910
    Crossref
    • Ashley M. Wabnitz,
    • Tanya N. Turan,
    Optimal Medical Management of Atherosclerotic Intracranial Stenosis, Stroke, 55, 2, (335-343), (2024).https://doi.org/10.1161/STROKEAHA.123.043633
    Crossref
    • Kay Sin Tan,
    • Jeyaraj Durai Pandian,
    • Liping Liu,
    • Kazunori Toyoda,
    • Thomas Wai Hon Leung,
    • Shinichiro Uchiyama,
    • Sathoshi Kuroda,
    • Nijasri C. Suwanwela,
    • Sanjith Aaron,
    • Hui Meng Chang,
    • Narayanaswamy Venketasubramanian,
    Stroke in Asia, Cerebrovascular Diseases Extra, (1-1), (2024).https://doi.org/10.1159/000538928
    Crossref
    • Rohit Bhatia,
    • MV Padma Srivastava,
    • Risha Sarkar,
    • Saman Fatima,
    • Imnameren Longkumer,
    • Ajay Garg,
    • Pooja Gupta,
    • Jeyaraj Durai Pandian,
    • Dheeraj Khurana,
    • PN Sylaja,
    • Shweta Jain,
    • Deepti Arora,
    • Aneesh Dhasan,
    • Meenakshi Sharma,
    STENOSIS: Long-term single versus dual antiplatelet therapy in patients with ischaemic stroke due to intracranial atherosclerotic disease – a randomised trial, BMJ Neurology Open, 6, 1, (e000532), (2024).https://doi.org/10.1136/bmjno-2023-000532
    Crossref
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF